Indi Molecular Picks Up $300K More In $1.8M Seed Funding

Culver City-based Indi Molecular, a developer of synthetic replacements for antibodies, announced Tuesday that it has raised $300,000 more in its seed funding, bringing the total raised in the round to $1.8M. The new funding was led by InterWest Partners, and also included several un-named, angel investors. The company said the funding will go towards further developing its technology, which its says can product synthetic peptide molecules that are equivalent or superior to molecular antibodies. Indi Molecular's technology is based on research out of the California Institute of Technology (Caltech). More information »